The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

Jeffrey W. Jacobs net worth and biography

Jeffrey Jacobs Biography and Net Worth

Insider of Ardelyx

Presently, Jeffrey W. Jacobs is Chief Scientific Officer for Ardelyx, Inc.

In his past career Dr. Jacobs was Principal at Affymax, Inc., Principal at Vicuron Pharmaceuticals LLC, Senior Director-Development Chemistry at Sunesis Pharmaceuticals, Inc. and Principal at The Damon Runyon Cancer Research Foundation.

Dr. Jacobs received an undergraduate degree from Gonzaga University and a doctorate from the University of California, Berkeley.

What is Jeffrey W. Jacobs' net worth?: The estimated net worth of Jeffrey W. Jacobs is at least $601,745.76 as of December 21st, 2020. Dr. Jacobs owns 92,862 shares of Ardelyx stock worth more than $601,746 as of April 20th. This net worth approximation does not reflect any other assets that Dr. Jacobs may own. Learn More about Jeffrey W. Jacobs' net worth.
How do I contact Jeffrey W. Jacobs?: The corporate mailing address for Dr. Jacobs and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on Jeffrey W. Jacobs' contact information.
Has Jeffrey W. Jacobs been buying or selling shares of Ardelyx?: Jeffrey W. Jacobs has not been actively trading shares of Ardelyx over the course of the past ninety days. Most recently, Jeffrey W. Jacobs sold 5,000 shares of the business's stock in a transaction on Monday, November 15th. The shares were sold at an average price of $1.13, for a transaction totalling $5,650.00. Learn More on Jeffrey W. Jacobs' trading history.
Who are Ardelyx's active insiders?: Ardelyx's insider roster includes Robert Blanks (Insider), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Michael Raab (CEO), David Rosenbaum (Insider), and Scott Sandell (Major Shareholder). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?: In the last year, insiders at the biopharmaceutical company sold shares 31 times. They sold a total of 643,508 shares worth more than $3,874,269.01. The most recent insider tranaction occured on April, 15th when CEO Michael Raab sold 7,500 shares worth more than $52,950.00. Insiders at Ardelyx own 5.5% of the company. Learn More about insider trades at Ardelyx.
Information on this page was last updated on 4/15/2024.

Jeffrey W. Jacobs Insider Trading History at Ardelyx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2021	Sell	5,000	$1.13	$5,650.00
12/21/2020	Sell	3,949	$6.88	$27,169.12	92,862
9/16/2020	Sell	50,804	$5.63	$286,026.52
10/11/2016	Sell	6,000	$15.00	$90,000.00
11/27/2015	Sell	2,000	$20.00	$40,000.00	47,420
10/8/2015	Sell	2,000	$19.88	$39,760.00	47,420
9/10/2015	Sell	2,000	$20.59	$41,180.00	47,420
2/4/2015	Sell	8,888	$16.28	$144,696.64

Jeffrey W. Jacobs Buying and Selling Activity at Ardelyx

Ardelyx Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $6.48

$6.27

$6.56

50 Day Range

MA: $8.13

$6.44

$9.73

2 Week Range

Now: $6.48

$3.16

$10.13

Volume

5,643,598 shs

Average Volume

6,131,967 shs

Market Capitalization

$1.51 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85